반응식
[CH3:1][S:2]([C:5]1[CH:6]=[C:7]2[C:11](=[CH:12][CH:13]=1)[NH:10][CH:9]=[CH:8]2)(=[O:4])=[O:3].Cl[C:15]1[N:20]=[C:19]([O:21][CH:22]2[CH2:27][CH2:26][N:25]([C:28]([O:30][C:31]([CH3:34])([CH3:33])[CH3:32])=[O:29])[CH2:24][CH2:23]2)[CH:18]=[CH:17][CH:16]=1>>[C:31]([O:30][C:28]([N:25]1[CH2:26][CH2:27][CH:22]([O:21][C:19]2[CH:18]=[CH:17][CH:16]=[C:15]([N:10]3[C:11]4[C:7](=[CH:6][C:5]([S:2]([CH3:1])(=[O:4])=[O:3])=[CH:13][CH:12]=4)[CH:8]=[CH:9]3)[N:20]=2)[CH2:23][CH2:24]1)=[O:29])([CH3:34])([CH3:32])[CH3:33]참가 물질
3
실험 절차
The title compound was prepared by following the similar procedure as described in Example-1 by using 5-(methylsulfonyl)-1H-indole (intermediate 21) and tert-butyl 4-((6-chloropyridin-2-yl)oxy)piperidine-1-carboxylate (intermediate 42) (0.19 g, 63%).
출처 및 근거
- ORD 기록
- ord-6f284c440ce84d7e9e4fab3eee15d0a4
- 출처 데이터셋
- uspto-grants-2015_04
- 특허 번호
- US09000175B2
연결된 노트
불러오는 중…